Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Goodwill: 2022-2025

Historic Goodwill for Axsome Therapeutics (AXSM) over the last 4 years, with Sep 2025 value amounting to $12.0 million.

  • Axsome Therapeutics' Goodwill changed negligibly% to $12.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.0 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $12.0 million for FY2024, which is negligibly% changed negligibly from last year.
  • Axsome Therapeutics' Goodwill amounted to $12.0 million in Q3 2025, which was down 0.00% from $12.0 million recorded in Q2 2025.
  • Axsome Therapeutics' Goodwill's 5-year high stood at $12.0 million during Q2 2023, with a 5-year trough of $10.3 million in Q4 2022.
  • Moreover, its 3-year median value for Goodwill was $12.0 million (2025), whereas its average is $11.9 million.
  • Data for Axsome Therapeutics' Goodwill shows a peak YoY grew of 16.80% (in 2023) over the last 5 years.
  • Axsome Therapeutics' Goodwill (Quarterly) stood at $10.3 million in 2022, then increased by 16.80% to $12.0 million in 2023, then remained steady at $12.0 million in 2024, then remained steady at $12.0 million in 2025.
  • Its Goodwill was $12.0 million in Q3 2025, compared to $12.0 million in Q2 2025 and $12.0 million in Q1 2025.